Therapeutic effects of dengue 2 virus capsid protein and staphylococcal nuclease fusion protein on dengue-infected cell cultures.
Dengue infection poses a serious public health problem in most tropical and subtropical areas. No effective antiviral drugs or vaccines are currently available against dengue infection. To explore the feasibility of using capsid-targeted viral inactivation (CTVI) as an antiviral strategy against dengue infection, we constructed a plasmid expressing a fusion protein consisting of staphylococcal nuclease (SN) fused to dengue 2 virus capsid protein (D2C), and investigated its effects on the production of infectious virions when introduced into BHK cells infected with dengue virus. The results indicated that D2C-SN can be expressed and tolerated in this mammalian cell culture. The enzymatically active SN moiety was incorporated into nascent virions during the process of viral assembly. By comparing the effects of incorporated SN and SN*, an enzymatically inactive missense mutant form of wild-type SN, on the infectivity of progeny virions, we clearly demonstrated that nucleolytic activity was the major antiviral mechanism. Expression of D2C-SN fusion protein as a therapeutic agent resulted in a reduction in infectious titers of 12- to 60-fold. Therefore, dengue virus may be particularly vulnerable to a CTVI therapeutic approach.
Qin
C-F
CF
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, P.R. China. qinede@sohu.com
Qin
E
E
Yu
M
M
Chen
S-P
SP
Jiang
T
T
Deng
Y-Q
YQ
Duan
H-Y
HY
Zhao
H
H
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D006224:Cricetinae; D003715:Dengue / Q000188:drug therapy*; D003716:Dengue Virus / Q000187:drug effects; D006801:Humans; D007668:Kidney; D007700:Kinetics; D008836:Micrococcal Nuclease / Q000235:genetics / Q000494:pharmacology*; D010957:Plasmids; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D014162:Transfection; D014759:Viral Envelope Proteins / Q000235:genetics / Q000494:pharmacology*; D014771:Virion / Q000187:drug effects
D000998:Antiviral Agents; C051821:E-glycoprotein, Dengue virus type 2; D011993:Recombinant Fusion Proteins; D014759:Viral Envelope Proteins; D008836:Micrococcal Nuclease